
- Industry news
Industry news
- Category news
- Reports
- Key trends
- Multimedia
Multimedia
- Journal
- Events
- Suppliers
Suppliers
- Home
- Industry news
Industry news
- Category news
- Reports
- Key trends
- Multimedia
Multimedia
- Events
- Suppliers
Suppliers
Lallemand Flagship Probiotic Formula Lacidofil Reduces Duration of Antibiotic-Associated Diarrhea

01 Jun 2016 --- A clinical study has confirmed the benefits of Lallemand’s Lacidofil probiotic formula (Lactobacillus rhamnosus Rosell-11 and Lactobacillus helveticus Rosell-52) in the management of antibiotic-associated diarrhea (AAD).
The study, led by Dr Malkanthi Evans of KGK Synergize Inc., was conducted in Canada. ADD episodes were reduced by 24 hours on average. The findings will be published in the British Journal of Nutrition.

The randomized double-blind, placebo controlled trial was conducted on 146 healthy adults. The subjects received a broad spectrum antibiotic treatment (amoxicillin-clavulanic acid) for one week in addition to the probiotic or placebo, followed by one week of probiotic alone. Patients were followed-up for up to nine weeks after the beginning of the treatment.
Moreover, this is the first study to demonstrate this beneficial effect with probiotics on AAD in a population of healthy adults.
It appeared that both probiotic strains survived the intestinal tract when administered concomitantly with the antibiotic, confirming the compatibility of Lacidofil with broad spectrum antibiotic treatment amoxicillin-clavulanic acid.
See more of our coverage in
your Google search results
Upcoming webinars

The future of infant nutrition: From science to success
Valio

From tiny guts to big impact: the powerful potential of probiotics in children’s health
Novonesis

Inside GLP-1 lives: real consumer insights to inspire innovation
FrieslandCampina Ingredients










